iTeos Therapeutics Enters Into Therapeutic Antibody Discovery Partnership with Adimab

Gosselies, Belgium – January 18, 2016 – iTeos Therapeutics SA, a biotechnology company with a track record of delivering therapeutics targeting the immune tumor micro-environment, today announced a new partnership for the discovery, development and commercialization of  multiple, antibody-based therapeutic programs with Adimab, LLC. Under the terms of the agreement, Adimab will utilize its antibody discovery and optimization platform to identify fully human therapeutic antibodies against targets selected by iTeos Therapeutics. All product development, including manufacturing and clinical trials, will be coordinated by iTeos Therapeutics.

“We are very pleased to enter into this partnership with an emerging leader in the oncology field.  iTeos has a strong management team and has demonstrated the capability to quickly develop valuable therapeutic programs,” said Tillman Gerngross, Chief Executive Officer of Adimab. “We are looking forward to applying the Adimab platform to discovering and engineering antibodies for iTeos.”.

“Adimab is clearly an excellent strategic partner for iTeos Therapeutics. The speed and the quality of Adimab’s platform has consistently generated candidate drugs that are superior to the output from competing technologies,” said Christophe Quéva, Chief Scientific Officer of iTeos. “We are convinced that the Adimab platform will rapidly deliver to iTeos antibody drug candidates which will be clinically evaluated as monotherapy and in combination with leading immuno-oncology drugs to develop iTeos’ pipeline and partnering potentials for the benefit of patients with cancer.”

Over the past six years, Adimab has established partnerships with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Lilly, Genentech, Biogen, Novo Nordisk, Gilead, Kyowa Hakko Kirin, and GSK. Adimab’s partnerships range from single target funded discovery projects, to larger multi-target funded discovery collaborations, as well as full transfer and enablement of the Adimab Platform to pharmaceutical companies. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.

About iTeos Therapeutics SA

Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), has built a discovery platform to identify therapeutics targeting the immune tumor micro-environment to optimize cancer immunotherapy and is now positioned to help deliver the next generation of cancer immunotherapies. iTeos combines expertise in tumor immunology with drug discovery of small molecules and biologics. The company entered into a strategic collaboration with Pfizer in December 2014. iTeos is developing partnerships with top-tier academic and industrial partners to develop new programs. iTeos is supported by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development).

A-Mansia Biotech S.A. closes a €13m Series A financing round

catalysed by the initial support of VIVES

 

A-Mansia Biotech S.A. is active in the microbiome field based on pioneering research on Akkermansia muciniphila (A. muciniphila) from two well-known scientists, Prof. P. Cani (Université catholique de Louvain) and Prof. W.M. de Vos (Wageningen University). A-Mansia Biotech aims to commercialize novel nutritional products which could tackle the challenges of metabolic disorders linked to obesity.

 

VIVES has catalysed and accelerated the technology transfer from both universities by crystallising key ingredients for a pioneering spin-off: i) high quality of fundamental research, ii) public and private funds during the pre-incubation phase, iii) recruitment of an experienced and entrepreneurial CEO with a close collaboration with founding fathers, iv) corporate and licencing structuring and v) (pre)-seed capital.

 

Seventure Partners led the €13m Series A financing round only one year after the inception of A-Mansia Biotech.

 

Louvain-la-Neuve, 27th April 2018 - VIVES II - Louvain Technology Fund (VIVES) announces a €13m Series A financing round for A-Mansia Biotech S.A., a co-spin-off of Wageningen University (WUR) and Université catholique de Louvain (UCL). The investor syndicate is led by Seventure Partners, an investment fund specialized in the field of the microbiome, and further supported by SRIW, Nivelinvest, individual investors as well as an additional €3m non-dilutive funding from the Walloon Region.

 

The research behind this new spin-off dates back to 2004 with the discovery of the bacterium Akkermansia muciniphila. The two founding fathers are head of complementary university teams and together proved that daily administration of live A. muciniphila is able to prevent the development of metabolic disorders and inflammatory condition in mice fed with a high-fat diet.  Pasteurised A. muciniphila exhibited additional beneficial effects. A first human exploratory study in volunteers was conducted at UCL’s Saint-Luc University Hospital between 2015 and February 2018. Intermediate results confirm that the bacterium is safe and well tolerated. As subjects with an increased cardio-metabolic risk (insulin resistance, hyperglycemia, high blood cholesterol, and visceral fat accumulation) are characterized by lower A. muciniphila abundance in the gut, this supplement could be key to maintain health and immunity, normal glycemia, normal blood cholesterol levels, and avoid excessive weight gain.

 

VIVES, together with its partners of the technology transfer offices at UCL and Wageningen University, was instrumental to support the creation of this first inter-university and international spin-off in the field of the microbiome.

 

A-Mansia Biotech, located in the Louvain incubator, will use the proceeds to develop novel nutritional products based on A. muciniphila up to the market launch and to develop a pharmaceutical research pipeline based on active components isolated from A. muciniphila.

 

Jean-Christophe Malrieu, CEO of A-mansia Biotech, joined the team in 2017 and brings a solid track record in the nutrition and health field as well as a strong expertise in business development and marketing. “Raising €13m in a series A for a university project within 12 months from inception of the company is a big success. We are now funded and supported to reach our first concrete milestone by 2021, the introduction of a new microbiome based nutritional product on the market.”

 

This is a unique opportunity to transform the output from the scientific discoveries made in UCL and Wageningen University’s laboratories into products for the benefit of everyone,” jointly explain Prof. P. Cani of UCL and Prof. W. M. de Vos , scientific co-founders.

 

VIVES Fund has been key to cement this “inter-university” and “cross-border” venture, due to its expertise in the creation from scratch of pioneering spin-off, through deep understanding of market needs, executive management, corporate and licencing structuring. Thanks to our close collaboration with the Louvain Technology Transfer Office (LTTO), we have been privileged to see this project showing impressive evolution over the last years. Our intense and fruitful collaboration with our colleagues at Wageningen University, led to this major financing round, a first successful step that we would like to replicate in the future. », adds Philippe Durieux, CEO VIVES.

 

About A-Mansia Biotech

Incorporated in 2016, A-Mansia Biotech is a Belgian-based microbiome start-up based on discoveries made by its founding scientists, Professor W.M. de Vos, from Wageningen University, The Netherlands, and Professor Patrice D. Cani, from the Université catholique de Louvain (UCL), Belgium. A-Mansia Biotech develops health products based on the unique properties of the Akkermansia muciniphila bacterium. The Company has secured €13m in a Series A financing round led by Seventure Partners together with VIVES, SRIW, Nivelinvest and individual investors.

 

About VIVES II - Louvain Technology Fund

The VIVES II - Louvain Technology Fund (VIVES) is a multi-sector technology fund which invests in the spin-offs of the Université catholique de Louvain (UCL) and start-ups in Belgium and neighboring countries. VIVES II is funded by EUROPEAN INVESTMENT FUND (EIF), SFPI-FPIM, BNP PARIBAS, BPI FRANCE (France), ING BELGIUM, SOFINA, AXA BELGIUM, BELFIUS, IRD (France), NIVELINVEST, REGION BRUXELLES CAPITALE and by SOPARTEC. The objective of the fund is to invest in the development of start-ups, from validation of the technology to commercial maturity. The €43 million fund is managed by SOPARTEC, UCL’s fully owned technology transfer company. Key investee companies: KEEMOTION, ITEOS THERAPEUTICS, NOVADIP BIOSCIENCES, SMARTNODES, EMOLYTICS, TESSARES, 3D-SIDE, AXINESIS, G2C, SYNDESI, APHEA, VIROVET, OLYGOSE, UPSTREEM, E-PEAS, A-MANSIA BIOTECH.

 

Some figures.

As per today, VIVES has invested in 17 invested companies which have collectively collected more €170 million through public and private funding. Their shareholders are prestigious investors: Fund+, Johnson & Johnson, Pfizer, Partech, Proximus, Semtech, SFPI-FPIM, New Science Venture, V-Bio Ventures, PMV, NOVO, Capagro, Emertech, SRIW, Nivelinvest, KUL, AIF, LICR, and Seventure. Those invested companies are managed by seasoned CEOs, backed by renowned scientists and senior directors.

VIVES has realized two exits.

 

About Louvain Technology Fund - LTTO

The Louvain Technology Transfer Office (LTTO) composed of SOPARTEC and UCL’s Administration of Research (ADRE), covers the entire technology transfer process: funding of the research contracts, identification of the inventions in the laboratories, protection and management of the intellectual property and the technological maturation and commercialization (via licenses and/or spin-off). More in particular, SOPARTEC coordinates the management of licensing and the evolution towards maturity of UCL’s spin-off projects. Over 70 spin-offs, generating today more than 2.000 jobs, have been created partly or completely based on the result of research, conducted at UCL.

 

 


 

Contact press

VIVES

Philippe Durieux

Tel: + 32 10 39 00 21

moc-cetrapos+xueirud-p

 

 

Jean-Christophe Malrieu (CEO of A-Mansia Biotech)

Tel: + 32 2 880 62 53 or

Mobile:  + 33 6 78 54 99 04

moc-aisnam-a+ueirlam-ehpotsirhc-naej

 

 

Louvain-la-Neuve / Brussels, Belgium – 21 April 2016 –ARGENX announced today having signed a major deal with AbbVie in the field of immuno-oncology. This deal is the result of a highly productive collaboration between ARGENX, a biotech company, and the teams of Professors Pierre Coulie and Sophie Lucas of the  Université catholique de Louvain (UCL), who are recognized worldwide as leaders in the field of immuno-oncology. This collaboration has resulted in an innovative therapeutic approach to stimulate the immune system of cancer patients.

 

Read more

Gosselies, Belgium – January 18, 2016 – iTeos Therapeutics SA, a biotechnology company with a track record of delivering therapeutics targeting the immune tumor micro-environment, today announced a new partnership for the discovery, development and commercialization of  multiple, antibody-based therapeutic programs with Adimab, LLC. Under the terms of the agreement, Adimab will utilize its antibody discovery and optimization platform to identify fully human therapeutic antibodies against targets selected by iTeos Therapeutics. All product development, including manufacturing and clinical trials, will be coordinated by iTeos Therapeutics.

“We are very pleased to enter into this partnership with an emerging leader in the oncology field.  iTeos has a strong management team and has demonstrated the capability to quickly develop valuable therapeutic programs,” said Tillman Gerngross, Chief Executive Officer of Adimab. “We are looking forward to applying the Adimab platform to discovering and engineering antibodies for iTeos.”.

“Adimab is clearly an excellent strategic partner for iTeos Therapeutics. The speed and the quality of Adimab’s platform has consistently generated candidate drugs that are superior to the output from competing technologies,” said Christophe Quéva, Chief Scientific Officer of iTeos. “We are convinced that the Adimab platform will rapidly deliver to iTeos antibody drug candidates which will be clinically evaluated as monotherapy and in combination with leading immuno-oncology drugs to develop iTeos’ pipeline and partnering potentials for the benefit of patients with cancer.”

Over the past six years, Adimab has established partnerships with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Lilly, Genentech, Biogen, Novo Nordisk, Gilead, Kyowa Hakko Kirin, and GSK. Adimab’s partnerships range from single target funded discovery projects, to larger multi-target funded discovery collaborations, as well as full transfer and enablement of the Adimab Platform to pharmaceutical companies. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.

About iTeos Therapeutics SA

Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), has built a discovery platform to identify therapeutics targeting the immune tumor micro-environment to optimize cancer immunotherapy and is now positioned to help deliver the next generation of cancer immunotherapies. iTeos combines expertise in tumor immunology with drug discovery of small molecules and biologics. The company entered into a strategic collaboration with Pfizer in December 2014. iTeos is developing partnerships with top-tier academic and industrial partners to develop new programs. iTeos is supported by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development).

An innovative approach for a metrics-oriented company and industry

05 OCTOBER 2015, BELGIUM
SUMMARY

In order to measure how Telenet’s customers feel about the company’s daily efforts to deliver pleasurable and meaningful experiences, Telenet has selected GetSmily to track and analyze its customers’ Emoscore (a unique method developed by the UCL spin-off). Thanks to this unique technology, Telenet will be able to assess how its customers feel and experience the company’s digital services and products.

Customer behaviour is evolving fast, and every company should be able to adapt to new challenges in terms of customer support, digital experiences, and relationships. “From day one, I understood the benefits of collecting customer feedback 24/7 in order to feed our digital team with real-time and topical customer insights,” explains Jeremy Curtin, Director of Digital at Telenet. “GetSmily is a great opportunity for Telenet to integrate a unique and innovative technology: Emolytics. In a rapidly changing environment, we need simple yet robust indicators that allow us to remain agile and in sync with our customers’ experiences and expectations; needless to say that we want to use solutions that does not interfere with their journey. Still, we need in-depth and actionable insights on which we can take action to improve the platforms we build for them,” Curtin concludes.

“GetSmily is very excited to welcome Telenet as a customer. This partnership demonstrates that the scientific work done around our technology for the last 3 years is reaching the heart of major players in competitive environments, where the customer is at the center of the business priorities,” says David Hachez, CEO and co-founder of GetSmily. “We believe that customer experience measurement is key for companies if they want to succeed in the years to come. All the communications and marketing efforts in which they invest human and financial capital need a strong ROI proof. What better than the emotions that drive customer behaviour to evaluate their performance?”

 

Louvain-la-Neuve, Belgium - September 10, 2015 – Novadip Biosciences, a biopharmaceutical spin-off company of Université catholique de Louvain announces the successful closing of a €28M Series A financing led by New Science Ventures, a US-based venture capital firm, and including Belgian investors VIVES Louvain Technology Fund, NivelInvest (Start-Up), Fund+, Integrale, SRIW, SFPI-FPIM, Epimède and several individual investors.

The proceeds of the capital round (€28M) and repayable advance from Belgium’s Walloon Region (€2M) will be primarily used for clinical development and process industrialization of Novadip Biosciences’ lead compound Creost®.

Neurotech spin-off from the Université catholique de LouvainLouvain-la-Neuve, Belgium- November 12th, 2012 – SORIN, a global medical devices company and a leader in the treatment of cardiovascular diseases, has acquired NeuroTECH, a spin-off of Université catholique de Louvain (UCL).

Management Buy-Out at Telemis, a spin-off of the Université catholique de Louvain (« UCL ») and leader in medical imaging.

 

Louvain-la-Neuve, October 10, 2012, Nivelinvest and Sopartec announced the disposal of their majority stake in Telemis, a spin-off of the division of applied mathematics (ICTEAM) at Université catholique de Louvain. This operation has been carried out in the context of a management buy-out (MBO).

Louvain-la-Neuve, Belgium- September 27th, 2012 - MSC Software, one of the ten original software companies and the worldwide leader in multidiscipline simulation, has acquired e-Xstream engineering, a spin-off of the Division of Applied Mechanics (MEMA) at the Université catholique de Louvain (UCL), the worldwide leader in multiscale simulation.

testLes « Petits-Déjeuners Rencontres » de la Sopartec sont nés en décembre 2007. L’objectif de ces rencontres est de favoriser le rapprochement des personnes impliquées dans le processus de valorisation de la recherche universitaire